Tesamorelin

Overview

Tesamorelin (TH9507) is a synthetic analogue of human growth hormone-releasing hormone (GHRH) comprising the full 44-amino-acid sequence of endogenous GHRH, modified at the N-terminus with a trans-3-hexenoic acid moiety to confer resistance to DPP-IV-mediated cleavage. This modification extends its plasma half-life while preserving full binding affinity at the pituitary GHRH receptor.

Unlike truncated GHRH analogues, tesamorelin engages the receptor with the native full-length peptide configuration, producing robust, sustained GH secretion with downstream elevation of IGF-1. It is one of the most extensively characterized synthetic GHRH analogues in clinical research, with a substantial body of controlled trial data examining its effects on body composition — particularly visceral adipose tissue.

Research Highlights

Clinical trials have documented tesamorelin's ability to significantly reduce visceral adipose tissue (VAT) — the metabolically active fat depot surrounding abdominal organs — as well as hepatic fat content and liver-associated inflammatory markers. Research has also characterized improvements in lean muscle mass, lipid profiles (particularly LDL reduction), and cognitive function in aging populations following sustained GH axis stimulation.

Beyond body composition, research groups have investigated tesamorelin's effects on recovery from exercise-induced muscle stress, cardiovascular risk factor modulation, and immune function enhancement. Its selectivity for the GH axis — stimulating pulsatile GH release without directly activating other hormonal systems — is a frequently cited advantage in longitudinal research designs.

For research use only. Not intended for human consumption.

Specifications

Certificate of Analysis

Each batch is independently tested by a third-party laboratory. A Certificate of Analysis (COA) confirming purity and identity is available upon request. Contact us with your order number to receive the COA for your specific lot.